Kenya BioVax Institute Limited

07/04/2026

Dr. Serah Muteru, GM, Regulatory Affairs, Product Quality and Safety, represented at the West Africa Biomanufacturing Regulation & Market Access Forum in Accra, Ghana, where leaders from across Africa convened to advance regulatory alignment, market access, sustainable financing and strategic partnerships for vaccines, sera and other biologics.

BioVax participated in the workshop as part of the discussions on capacity-building priorities for biomanufacturing, contributing perspectives on strengthening regulatory and technical capacity, regional collaboration, and the systems needed to support sustainable local production and access to vaccines and other biologics in Africa.

🇰🇪 🇬🇭

02/04/2026

01/04/2026

Today, we joined colleagues across Kenya BioVax Institute in celebrating Anita Loko from the Supply Chain Management Division as she begins a new chapter in her career. We thank Anita for her dedication, professionalism, and the positive contribution she has made during her time with us. As she leaves for greener pastures, we wish her every success, growth, and fulfillment in the journey ahead.

Congratulations, Anita, and best wishes from all of us at Kenya BioVax Institute.

01/04/2026

As conversations on health product security continue to gain momentum across Africa, Médecins Sans Frontières / MSF Access convened an expert roundtable on 27 March to examine the promise and practical realities of local and regional manufacturing in Eastern and Southern Africa. The discussion brought together experts, including Dr. Serah Muteru of , Patrick Osewe, and Rosemary Mburu of , to explore whether local production can truly improve affordability, quality, supply security, equity, and resilience, especially in humanitarian settings. The roundtable also examined critical issues such as regulatory readiness, technology transfer, investment, market shaping, and the structural bottlenecks that continue to affect manufacturing on the continent, while calling for approaches that put public health needs and access at the center of Africa’s manufacturing agenda.

30/03/2026

EXTENSION OF SUBMISSION DEADLINE REQUEST FOR EXPRESSIONS OF INTEREST (CONSULTING SERVICES – FIRMS SELECTION)

26/03/2026

Building on earlier engagements, held a second strategic partnership meeting with representatives from (SBS) to deepen collaboration on strengthening Kenya’s health products manufacturing ecosystem. The discussions refined priority areas including regulatory capacity building, research and development, market access, workforce development, and joint financing. Through its Frontier Hub, Strathmore will complement BioVax’s infrastructure investments by strengthening human and institutional capacity in areas such as GMP compliance, quality systems, and regulatory pathways. The partnership aligns with Kenya’s broader health system strengthening efforts, with next steps focused on launching technology transfer learning programs.

18/03/2026

A courtesy visit by officials from the French Embassy Trade Department, Mr. Brandon Opondo and Mr. Abubakar Bakari, accompanied by Stephane Raharijaona of Systems, provided an opportunity to engage BioVax leadership in strategic discussions on advancing local vaccine manufacturing and health technologies. The meeting brought together the CEO alongside technical and strategic planning teams to explore areas of collaboration, strengthen trade relations between France and the East African Community, and align ahead of the upcoming France–Africa Health Summit to be held in Nairobi.

This engagement reflects the growing importance of international partnerships in accelerating Africa’s health security and local manufacturing agenda. 🌍🤝🇰🇪🇫🇷

17/03/2026

As part of the ongoing -MPP mRNA Technology Transfer Programme, , in collaboration with , convened a capacity-building workshop with its technical team to strengthen competencies in mRNA vaccine manufacturing and related bioprocessing systems. The workshop focused on enhancing practical skills, technology transfer readiness, and operational excellence required to support the establishment of local vaccine production capabilities. This engagement marks a key step in building the technical expertise necessary to deliver on Kenya’s ambition for sustainable vaccine manufacturing and improved health security across the region. 💉🇰🇪

13/03/2026

The Kenya BioVax Institute Board formalized its Performance Contract for FY 2025/2026 by signing the agreement between the Board and the Chief Executive Officer, Dr. Wesley Ronoh. The Board was represented by the Chairman, Dr. Charles Githinji, accompanied by Board Member Harrison Wangoro Mwangi. The signing marks an important step in strengthening performance accountability and institutional leadership as BioVax continues advancing Kenya’s agenda for local vaccine manufacturing, health security, and sustainable biotechnology capacity. 💉🇰🇪

11/03/2026

Call for Expressions of Interest (Consulting Services - Firms Selection)

Kenya BioVax Institute invites eligible consulting firms to submit Expressions of Interest (EOI) to provide:

CONSULTING SERVICES FOR TRANSACTION ADVISORY SERVICES ON ACQUISITION OF TECHNOLOGY TRANSFER CONTRACTS FOR THE KENYA BIOVAX INSTITUTE

Please click the link for more details:https://biovax.go.ke/wp-content/uploads/2026/03/TRANSACTION-ADVISORY-ADVERT.pdf

Also, for more tender opportunities, please click the link : https://
biovax.go.ke/tenders/

Africa CDC